Comparative Analysis of Gremlin-1, Syndecan-4 and IL-1 Beta Levels in Gingival Crevicular Fluid Among İndividuals With Periodontal Health and Stage III Periodontitis, Considering Both Smokers and Non-Smokers, Before and After Non-Surgical Periodontal Therapy

Launched by TUGBA AYDIN · Nov 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of smoking on certain biological markers in the saliva of individuals with Stage III periodontitis, a serious gum disease that can lead to tooth loss. Researchers want to understand how smoking influences levels of Gremlin-1, Syndecan-4, and IL-1 Beta, which are proteins that play important roles in inflammation and tissue health. By comparing the levels of these markers before and after non-surgical periodontal treatment in both smokers and non-smokers, the study aims to improve early detection and treatment strategies for periodontal disease.

To be eligible for this study, participants should be between 18 and 60 years old and must not have any other health conditions. There are two main groups being studied: non-smoking patients with Stage III periodontitis and smoking patients with the same condition, both of whom must meet specific clinical criteria. Participants can expect to have their gum health evaluated and their saliva tested before and after treatment to help researchers learn more about the impact of smoking on gum disease. It's important to note that those who have received periodontal treatment in the last six months or have certain health issues cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The volunteers must not have any systemic diseases.
• • The volunteers must be between 18 and 60 years of age.
• • Control group: Periodontally healthy patients with no signs of periodontal disease and no history of smoking.
• • Study Group I: Non-smoking patients with stage III periodontitis, evaluated based on clinical findings such as PD ≥ 5 mm and CAL ≥ 4 mm (with ≥ 30% of affected teeth), without radiographic evidence of bone loss and a history of smoking.
• • Study Group II: Smoking patients with untreated stage III periodontitis, evaluated based on clinical findings such as PD ≥ 5 mm and CAL ≥ 4 mm (with ≥ 30% of affected teeth), with radiographic evidence of bone loss and a history of smoking for at least 10 cigarettes per day over the past 3 years.
• Exclusion Criteria:
• • The individual's unwillingness to participate in the study
• • Being outside the specified age range
• • Pregnant or breastfeeding patients
• • Having a systemic disease
• • Smoking in the past 10 years
• • Having received periodontal treatment within the last 6 months